報價延遲最少15分鐘:2025/09/05 18:01 EDT
盤後時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.09/-6.33
|
|
企業價值
17.08M
|
| 資產負債 |
|
每股賬面淨值
1.08
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
8.00K
|
|
每股收益
0.04
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/05 18:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformativetreatments for serious diseases. |
